ClinicalTrials.gg
Not yet recruitingNCT07939919Updated Nov 16, 2026

A Study of AK158D1 in Advanced Solid Tumors

A Phase 1 interventional study of AK158D1 in Solid Malignant Tumor, sponsored by Akeso. Not yet recruiting at 2 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Akeso · Phase 1, Interventional, and Treatment

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
349
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is a first-in-human, phase I clinical study aimed at evaluating the safety, tolerability, pharmacokinetics and preliminary antitumor efficacy of AK158D1 in advanced solid tumors.

02

Conditions studied

  • Solid Malignant Tumor
03

In context

Lead sponsor

Akeso is the lead sponsor of 157 studies on the registry; 67 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able to understand and voluntarily sign a written form, which must be signed prior to the performance of the designated study procedures required by the study.
  2. Age ≥ 18 and ≤75 years old, both male and female.
  3. (ECOG) performance status score of 0 or 1.
  4. Expected survival ≥ 3 months.
  5. At least one that is suitable for repeated and accurate measurements according to v1.1.
  6. Histologically or cytologically, confirmed advanced solid tumors.
  7. Adequate organ function.

Exclusion criteria

Exclusion Criteria:

  1. Presence of brain stem , meningeal metastases, spinal cord compression or metastases.
  2. Presence of active central nervous system (CNS) metastases.
  3. Previous anti-tumor therapy toxicity has not been resolved.
  4. Have other within 3 years prior to enrollment.
  5. Known presence of active , , pulmonary tuberculosis, active syphilis infection.
  6. Have cardiovascular or cerebrovascular diseases.
  7. Other reasons for ineligibility as evaluated by investigator.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
349 participants (estimated)

Study arms

  • Experimental
    AK158D1

    Drug: AK158D1

Interventions

  • DrugAK158D1

    Subjects will receive AK158D1 via intravenous infusion (IV) in prespecified dose levels.

06

What researchers measure

Primary outcomes

  1. Dose Limiting Toxicities (DLTs)

    Dose Limiting Toxicities (DLTs) are defined as toxicities that meet pre-defined severity criteria, and assessed as having a suspected relationship to the study drug.

    Time frame: At the end of Cycle 1 (each cycle is 21 days)

  2. Adverse Events (AEs)

    Incidence and severity of adverse events (AEs) and clinically significant test abnormalities.

    Time frame: Up to approximately 2 years

Secondary outcomes

  1. Pharmacokinetics (PK) Characteristics

    Serum drug concentration profiles at different time points after administration.

    Time frame: Up to approximately 2 years

  2. Anti-Drug Antibodies (ADA)

    Number of subjects with detectable anti-drug antibodies (ADA).

    Time frame: Up to approximately 2 years

  3. Objective Response Rate (ORR)

    Objective Response Rate (ORR) is the proportion of participants with complete response(CR) or partial response(PR) , assessed based on RECIST v1.1.

    Time frame: Up to approximately 2 years

  4. Disease Control Rate (DCR)

    Disease control rate (DCR) assessed by investigator according to RECIST v1.1.

    Time frame: Up to approximately 2 years

  5. Duration of Response (DoR)

    Duration of response (DoR) assessed by investigator according to RECIST v1.1.

    Time frame: Up to approximately 2 years

  6. Time to Response (TTR)

    Time to response (TTR) is defined as the time to response assessed by investigator according to RECIST v1.1.

    Time frame: Up to approximately 2 years

  7. Progression Free Survival (PFS)

    Progression Free Survival (PFS) is defined as the time from randomization to the first documented disease progression (per RECIST v1.1) assessed by investigator or death due to any cause, whichever occurs first.

    Time frame: Up to approximately 2 years

  8. Overall Survival (OS)

    Overall Survival (OS) is defined as the time from randomization to death due to any cause.

    Time frame: Up to approximately 2 years

07

Study locations

2 sites
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for Apr 2028, 17 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 1, 2026
First posted
Nov 16, 2026
StartEst.
Nov 16, 2026
Primary completionEst.
Apr 30, 2028
CompletionEst.
Apr 30, 2030
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07939919
Lead sponsor
Akeso
Responsible party
Sponsor
First posted
Nov 16, 2026
Start date
Nov 16, 2026 (estimated)
Primary completion
Apr 30, 2028 (estimated)
Completion
Apr 30, 2030 (estimated)
Last update
Nov 16, 2026

Study contacts

Xufang Yu
Contact
clinicaltrials@akesobio.com
+86 (0760) 89873999

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion